ArticleImmunotherapy2022
Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy.
Article in Immunotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Optimizing management of immune checkpoint inhibitor-induced inflammatory arthritis: A case series and literature review.Experimental and therapeutic medicine · 2026Article
- Steroid-sparing strategies for managing immune-related adverse events.Journal for immunotherapy of cancer · 2026Review
- IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses.Cancer biology & medicine · 2025Article
- The clinical characteristics, mechanism and management of immune checkpoint inhibitor-related arthritis.Frontiers in immunology · 2025Review
- Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease.Rheumatology international · 2024Article
- Secukinumab May Be an Effective Treatment Option for Axial Spondyloarthritis and Psoriatic Arthritis Patients with a History of Malignancy: Multicenter Real-Life Experience from Turkey.Journal of clinical medicine · 2024Article
- The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review.Advances in therapy · 2024Review
- Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.The Journal of clinical investigation · 2024Observational
- The Roles of T cells in Immune Checkpoint Inhibitor-Induced Arthritis.Aging and disease · 2024Review
- Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.Rheumatic diseases clinics of North America · 2024Review
- Biological Agents for Treating Atezolizumab-Induced Psoriasis in Small-Cell Lung Cancer: A Case Report.Cureus · 2024Article
- Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.Medicina (Kaunas, Lithuania) · 2024Review
- Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy.European journal of rheumatology · 2024Article
- Drug- or Vaccine-Induced/Aggravated Psoriatic Arthritis: A Systematic Review.Dermatology and therapy · 2024Review
- A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review.International journal of molecular sciences · 2023Review
- Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.Journal for immunotherapy of cancer · 2023Article
- Article
- Current landscape and tailored management of immune-related adverse events.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-related adverse events (irAEs) are a major concern when treating cancer patients with immune checkpoint inhibitor (ICI) therapy. Selecting the most appropriate management of irAEs remains an ongoing challenge because prolonged use of glucocorticoids come with their own side effects and may counteract the antineoplastic effects from immunotherapy. In this case report, we present two patients with metastatic melanoma who developed symptoms of inflammatory arthritis attributed to ICI therapy. We found that treatment with secukinumab, an anti-IL-17A inhibitor, effectively managed their symptoms and did not lead to tumor progression. Our study suggests that secukinumab can be a safe and effective treatment option for ICI-induced inflammatory arthropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.